Tech Center 1600 • Art Units: 1600 1612 1638
This examiner grants 69% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18354719 | METHOD FOR PRODUCING FOOD PRODUCTS USING CELLS GROWN IN CULTURE AS AN ALTERNATIVE TO ANIMAL HUSBANDRY | Non-Final OA | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA |
| 18028740 | COMPOSITION AND METHODS FOR MODULATING TCF4 GENE EXPESSION AND TREATING PITT HOPKINS SYNDROME | Non-Final OA | The Regents of the University of California |
| 17957166 | METHOD OF CULTURING RECONSTRUCTED HUMAN SKIN | Non-Final OA | Korea University Research and Business Foundation |
| 18040971 | RECOMBINANT ADENO-ASSOCIATED VIRUS FOR TREATMENT OF GRN-ASSOCIATED ADULT-ONSET NEURODEGENERATION | Non-Final OA | The Trustees of the University of Pennsylvania |
| 17439733 | METHODS AND MATERIALS FOR TREATING CANCER | Final Rejection | The Penn State Research Foundation |
| 18248319 | DIALDEHYDE STARCH CROSSLINKED SCAFFOLD COMPOSITIONS AND METHODS | Non-Final OA | Scripps Health |
| 18047744 | COMPOSITIONS AND METHODS FOR TREATING MYELIN DEFICIENCY BY REJUVENATING GLIAL PROGENITOR CELLS | Non-Final OA | University of Rochester |
| 18054292 | POROUS DOUBLE-NETWORK HYDROGEL | Non-Final OA | THE ROYAL INSTITUTION FOR THE ADVANCEMENT OF LEARNING/MCGILL UNIVERSITY |
| 18021005 | GENE THERAPY USING NUCLEIC ACID CONSTRUCTS COMPRISING METHYL CPG BINDING PROTEIN 2 (MECP2) PROMOTER SEQUENCES | Non-Final OA | UCB BIOPHARMA SRL |
| 18410531 | PREDICTION OF STEM CELL THERAPY RESPONSIVENESS BY QUANTIFICATION OF PRE-EXISTING B REGULATORY CELLS | Non-Final OA | Therapeutic Solutions International, Inc. |
| 17686669 | EXPANDABLE LIVER ORGANOIDS, MEDIA COMPOSITION FOR DIFFERENTIATION THEREOF, AND METHOD FOR PRODUCING LIVER ORGANOIDS USING THE SAME | Non-Final OA | KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY |
| 17778194 | METHOD FOR FREEZING CELL AGGREGATES | Final Rejection | RACTHERA Co., Ltd. |
| 17926757 | NOVEL TRANSDUCTION ENHANCERS AND USES THEREOF | Final Rejection | Universität Zürich |
| 18066999 | METHOD FOR STABLY AMPLIFYING PLURIPOTENT STEM CELL | Final Rejection | Gwo Xi Stem Cell Applied Technology Co., Ltd. |
| 18355798 | DECELLULARIZED TISSUE-DERIVED EXTRACELLULAR MATRIX FUNCTIONALIZED WITH PHENOL DERIVATIVE AND USE THEREOF | Non-Final OA | CELLARTGEN INC. |
| 18257727 | GENE THERAPY FOR TREATING USHER SYNDROME | Non-Final OA | ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS |
| 18009476 | BACULOVIRUS EXPRESSION SYSTEMS | Non-Final OA | FLAGSHIP PIONEERING INNOVATIONS V, INC. |
| 18030613 | GENE THERAPY FOR OCULAR MANIFESTATIONS OF CLN2 DISEASE | Non-Final OA | Tern Therapeutics, LLC |
| 18029010 | COMPOSITION AND USES THEREOF | Non-Final OA | ScoutBio, Inc. |
| 17920661 | STEM CELL MEDIUM AND STEM CELL CULTURING METHOD | Final Rejection | Oriental Yeast Co., Ltd. |
| 17920355 | COMPOSITIONS FOR TREATING CANCER WITH KRAS MUTATIONS AND USES THEREOF | Non-Final OA | Aadigen, LLC |
| 17768363 | FUNCTIONAL CYTOCHROME P450 IN VITRO ASSAY | Non-Final OA | PharmGenetix GmbH |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy